In addition, the GLXB herb pair exerted therapeutic effects on dyslipidemia in ApoE-/- mice by increasing the level of butyric acid, a metabolite of the gut microbiota, decreasing the expression of NPC1L1, MTP, ACAT2, and ApoB48 proteins, and inhibiting the intestinal absorption of cholesterol. Here, ACAT2 is linked to metabolic syndrome.